Search jobs 11-Jan-2021 Anti-Rickettsial Treatment Market Outlook and Deep Study of Top Key Players | Allergan, Amneal Pharmaceuticals LLC., Strides Pharma Science Limited., Almirall, S.A
DBMR has added a new report titled Anti-Rickettsial Treatment Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The report forecasts the innovative applications of Anti-Rickettsial Treatment Market on the basis of these estimations. This market research analysis report starts with a basic introduction of the 2019 market segmentation, future scenario, industry growth rate, and industrial opportunities to 2028. Company profile comprises parameters such as company synopsis, commercial synopsis, work strategy and planning, SWOT analysis and present developments. The report gives out an outlook of the business chain structure and explains the industry environment, t
Aditya Puri joins as advisor to the Strides Group & Director of Stelis Biopharma equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Stelis poised for its next leg of growth, this is the right time to expand the board, and ensure robust guidance and governance by the best possible industry minds.
Strides Pharma may get transferred to a clutch of investors as promoters plan to exit
December 30, 2020
Company’s vaccine facility likely to go on stream in January
Strides Pharma Science Limited, with no successors to take the company forward, is at crossroads as promoters are planning to exit. With their plan to exit the company, it is learnt that the company may get transferred to a clutch of investors.
“The company is expected to be transferred to a clutch of investors as the promoters are looking to exit for personal reasons,” said a veteran pharma specialist, who did not want to be identified.
Strides receives USFDA approval for Oxybutynin Chloride Tablets
Posted On: 2020-12-18 02:41:57 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP, 5 mg is approximately US$ 29 Mn. The product will be manufactured at the company s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.